Minakem Generic APIs Minakem Generic APIs

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"CytRx Corporation","sponsor":"ImmunityBio","pharmaFlowCategory":"D","amount":"$343.0 million","upfrontCash":"Undisclosed","newsHeadline":"CytRx Corporation Highlights Significant Positive Events From its Licensed Drug Aldoxorubicin","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"CytRx Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytRx Corporation Highlights Latest Positive Event From its Licensed Drug Aldoxorubicin","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Centurion BioPharma","sponsor":"CytRx Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CytRx Announces Integration of Wholly Owned Subsidiary Centurion BioPharma and Corporate Governance Updates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"CytRx Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytRx Partners with Oncology Development Expert to Advance LADR Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"LadRx","sponsor":"ImmunityBio","pharmaFlowCategory":"D","amount":"$356.0 million","upfrontCash":"Undisclosed","newsHeadline":"LadRx and ImmunityBio Mutually Agree to Terminate Aldoxorubicin License","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"LadRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LadRx Highlights Patent Issued for Its LADR Technology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals for Aldoxorubicin

    Menu

    Aldoxorubicin

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              LadRx

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              LadRx and ImmunityBio Mutually Agree to Terminate Aldoxorubicin License

              Details:

              With the termination, LadRx regains control of INNO-206 (aldoxorubicin), a rationally-engineered cytotoxic which delivers well-established anti-cancer agent, doxorubicin, into the tumor.

              Lead Product(s): Aldoxorubicin

              Therapeutic Area: Oncology Product Name: INNO-206

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: ImmunityBio

              Deal Size: $356.0 million Upfront Cash: Undisclosed

              Deal Type: Termination June 03, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              LadRx

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              LadRx Highlights Patent Issued for Its LADR Technology

              Details:

              INNO-206 (aldoxorubicin) is a prodrug of doxorubicin that binds endogenous albumin after administration. The bound doxorubicin is released in the acidic environment of the tumor cell through cleavage of an acid sensitive linker and expresses antitumor efficacy and toxicity.

              Lead Product(s): Aldoxorubicin

              Therapeutic Area: Oncology Product Name: INNO-206

              Highest Development Status: Phase II Product Type:

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 27, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              CytRx Corporation

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              CytRx Partners with Oncology Development Expert to Advance LADR Platform

              Details:

              Aldoxorubicin, a rationally-engineered cytotoxic delivers well-established anti-cancer agent, doxorubicin, into tumor, utilizes an acid-sensitive linker that selectively binds to albumin, which may allow cytotoxic payload to preferentially accumulate in tumor.

              Lead Product(s): Aldoxorubicin

              Therapeutic Area: Oncology Product Name: INNO-206

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 20, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Centurion BioPharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Country
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              CytRx Announces Integration of Wholly Owned Subsidiary Centurion BioPharma and Corporate Governance Updates

              Details:

              Through the merger with Centurion, the next-generation LADR drugs including INNO-206, are now within CytRx and poised for the last steps required for first-in-human studies, an achievement that could be expected to generate significant value for shareholders.

              Lead Product(s): Aldoxorubicin

              Therapeutic Area: Oncology Product Name: INNO-206

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: CytRx Corporation

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Merger March 09, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              CytRx Corporation

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              CytRx Corporation Highlights Latest Positive Event From its Licensed Drug Aldoxorubicin

              Details:

              CytRx partner immunitybio announces the initiation of a Phase 2 registrational-intent study of its immunotherapy including aldoxorubicin in metastatic pancreatic cancer.

              Lead Product(s): Aldoxorubicin,Paclitaxel,Gemcitabine

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 21, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              CytRx Corporation

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              CytRx Corporation Highlights Significant Positive Events From its Licensed Drug Aldoxorubicin

              Details:

              CytRx out-licensed global development, manufacturing, and commercialization rights for aldoxorubicin to ImmunityBio Inc. in July 2017.

              Lead Product(s): Aldoxorubicin

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: ImmunityBio

              Deal Size: $343.0 million Upfront Cash: Undisclosed

              Deal Type: Agreement January 29, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Symbiotec: Global API manufacturer, specializing in Cortico-Steroids & Steroid-Hormone APIs.
              Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
              Post Enquiry
              POST ENQUIRY